Which medications should be used cautiously in patients who has been prescribed nitrate therapy?

Nitroglycerin forms free radical nitric oxide (NO) which activates guanylate cyclase, resulting in an increase of guanosine 3'5' monophosphate (cyclic GMP) in smooth muscle and other tissues. These events lead to dephosphorylation of myosin light chains, which regulate the contractile state in smooth muscle, and result in vasodilatation.

Pharmacodynamics

The principal pharmacological action of nitroglycerin is relaxation of vascular smooth muscle. Although venous effects predominate, nitroglycerin produces, in a dose-related manner, dilation of both arterial and venous beds. Dilation of postcapillary vessels, including large veins, promotes peripheral pooling of blood, decreases venous return to the heart, and reduces left ventricular end-diastolic pressure (preload).

Nitroglycerin also produces arteriolar relaxation, thereby reducing peripheral vascular resistance and arterial pressure (afterload), and dilates large epicardial coronary arteries; however, the extent to which this latter effect contributes to the relief of exertional angina is unclear.

Therapeutic doses of nitroglycerin may reduce systolic, diastolic, and mean arterial blood pressure. Effective coronary perfusion pressure is usually maintained, but can be compromised if blood pressure falls excessively, or increased heart rate decreases diastolic filling time.

Elevated central venous and pulmonary capillary wedge pressures, and pulmonary and systemic vascular resistance are also reduced by nitroglycerin therapy. Heart rate is usually slightly increased, presumably due to a compensatory response to the fall in blood pressure. Cardiac index may be increased, decreased, or unchanged. Myocardial oxygen consumption or demand (as measured by the pressure-rate product, tension-time index, and stroke-work index) is decreased and a more favorable supply-demand ratio can be achieved. Patients with elevated left ventricular filling pressures and increased systemic vascular resistance in association with a depressed cardiac index are likely to experience an improvement in cardiac index. In contrast, when filling pressures and cardiac index are normal, cardiac index may be slightly reduced following nitroglycerin administration.

Consistent with the symptomatic relief of angina, digital plethysmography indicates that onset of the vasodilatory effect occurs approximately 1 to 3 minutes after sublingual nitroglycerin administration and reaches a maximum by 5 minutes postdose. Effects persist for at least 25 minutes following NITROSTAT administration.

Pharmacokinetics

Absorption

Nitroglycerin is rapidly absorbed following sublingual administration of NITROSTAT tablets. Mean peak nitroglycerin plasma concentrations occur at a mean time of approximately 6 to 7 minutes postdose (Table 1). Maximum plasma nitroglycerin concentrations (Cmax) and area under the plasma concentration-time curves (AUC) increase dose-proportionally following 0.3 to 0.6 mg NITROSTAT. The absolute bioavailability of nitroglycerin from NITROSTAT tablets is approximately 40% but tends to be variable due to factors influencing drug absorption, such as sublingual hydration and mucosal metabolism.

Table 1

Distribution

The volume of distribution (VArea) of nitroglycerin following intravenous administration is 3.3 L/kg. At plasma concentrations between 50 and 500 ng/mL, the binding of nitroglycerin to plasma proteins is approximately 60%, while that of 1,2-and 1,3-dinitroglycerin is 60% and 30%, respectively.

Metabolism

A liver reductase enzyme is of primary importance in the metabolism of nitroglycerin to glycerol di-and mononitrate metabolites and ultimately to glycerol and organic nitrate. Known sites of extrahepatic metabolism include red blood cells and vascular walls. In addition to nitroglycerin, 2 major metabolites 1,2and 1,3-dinitroglycerin, are found in plasma. Mean peak 1,2-and 1,3-dinitroglycerin plasma concentrations occur at approximately 15 minutes postdose. The elimination half-life of 1,2-and 1,3-dinitroglycerin is 36 and 32 minutes, respectively. The 1,2-and 1,3-dinitroglycerin metabolites have been reported to possess approximately 2% and 10%, respectively, of the pharmacological activity of nitroglycerin. Higher plasma concentrations of the dinitro metabolites, along with their nearly 10-fold longer elimination half-lives, may contribute significantly to the duration of pharmacologic effect. Glycerol mononitrate metabolites of nitroglycerin are biologically inactive.

Elimination

Nitroglycerin plasma concentrations decrease rapidly, with a mean elimination half-life of 2 to 3 minutes. Half-life values range from 1.5 to 7.5 minutes. Clearance (13.6 L/min) greatly exceeds hepatic blood flow. Metabolism is the primary route of drug elimination.

Drug Interactions

Aspirin

Coadministration of nitroglycerin with high dose aspirin (1000 mg) results in increased exposure to nitroglycerin. The vasodilatory and hemodynamic effects of nitroglycerin may be enhanced by concomitant administration of nitroglycerin with high dose aspirin.

Tissue-Type Plasminogen Activator (t-PA)

Concomitant administration of t-PA and intravenous nitroglycerin has been shown to reduce plasma levels of t-PA and its thrombolytic effect.

Nitroglycerin comes as a sublingual tablet to take under the tongue. The tablets is usually taken as needed, either 5 to 10 minutes before activities that may cause attacks of angina or at the first sign of an attack. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take nitroglycerin exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Nitroglycerin may not work as well after you have used it for some time or if you have taken many doses. Take the fewest tablets needed to relieve the pain of your attacks. If your angina attacks happen more often, last longer, or become more severe at any time during your treatment, call your doctor.

Talk to your doctor about how to use nitroglycerin tablets to treat angina attacks. Your doctor will probably tell you to sit down and take one dose of nitroglycerin when an attack begins. If your symptoms do not improve very much or if they worsen after you take this dose you may be told to call for emergency medical help right away. If your symptoms do not go away completely after you take the first dose, your doctor may tell you to take a second dose after 5 minutes have passed and a third dose 5 minutes after the second dose. Call for emergency medical help right away if your chest pain has not gone away completely 5 minutes after you take the third dose.

Do not chew, crush, or swallow nitroglycerin sublingual tablets. Instead, place the tablet under your tongue or between your cheek and gum and wait for it to dissolve. You may feel burning or tingling in your mouth as the tablet dissolves. This is normal but is not a sign that the tablet is working. Do not be concerned that the tablet is not working if you do not feel the burning or tingling.

1. Roger VL, Go SA, Lloyd‐Jones DM, et al. Heart disease and stroke statistics—2011 update: a report from the American Heart Association [published corrections appear in Circulation. 2011;123:e240 and 2011;124:e426]. Circulation. 2011;123:e18–e209. [PMC free article] [PubMed] [Google Scholar]

2. World Health Organization . World Health Organization Fact Sheet No. 317: cardiovascular diseases (CVDs). http://www.who.int/mediacentre/factsheets/fs317/en/index.html. Published September 2011.. Accessed December 14, 2011.

3. Dougherty CM, Dewhurst T, Nichol WP, et al. Comparison of three quality of life instruments in stable angina pectoris: Seattle Angina Questionnaire, Short Form Health Survey (SF‐36), and Quality of Life Index‐Cardiac Version III. J Clin Epidemiol. 1998;51:569–575. [PubMed] [Google Scholar]

4. Brorsson B, Bernstein SJ, Brook RH, et al. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart. 2002;87:140–145. [PMC free article] [PubMed] [Google Scholar]

5. Lloyd‐Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association [published corrections appear in Circulation. 2010;121:e260 and 2011;124:e425]. Circulation. 2010;121:e46–e215. [Google Scholar]

6. Mangoni AA. Cardiovascular drug therapy in elderly patients: specific age‐related pharmacokinetic, pharmacodynamic and therapeutic considerations. Drugs Aging. 2005;22:913–941. [PubMed] [Google Scholar]

7. Daly C, Clemens F, Lopez‐Sendon JL, et al; Euro Heart Survey Investigators. The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. Eur Heart J. 2006;27:1298–1304. [PubMed] [Google Scholar]

8. Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double‐blind, placebo‐controlled MERLIN‐TIMI (Metabolic Efficiency With Ranolazine for Less Ischemia in Non‐ST‐Segment Elevation Acute Coronary Syndromes) 36 Trial. J Am Coll Cardiol. 2009;53:1510–1516. [PubMed] [Google Scholar]

9. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA Guidelines for the management of patients with unstable angina and non–ST‐segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) [published correction appears in Circulation. 2000;102:1739]. Circulation. 2000;102:1193–1209. [PubMed] [Google Scholar]

10. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341–1381. [PubMed] [Google Scholar]

11. Holubkov R, Laskey WK, Haviland A, et al; NHLBI Dynamic Registry Investigators. Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry. Am Heart J. 2002;144:826–833. [PubMed] [Google Scholar]

12. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary‐artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117–1124. [PubMed] [Google Scholar]

13. Serruys PW, Ong AT, van Herwerden LA, et al. Five‐year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46:575–581. [PubMed] [Google Scholar]

14. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503–1516. [PubMed] [Google Scholar]

15. Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary‐artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360:961–972. [PubMed] [Google Scholar]

16. Javitz HS, Ward MM, Watson JB, et al. Cost of illness of chronic angina. Am J Manag Care. 2004;10(11 suppl):S358–S369. [PubMed] [Google Scholar]

17. Deedwania PC, Carbajal EV. Medical therapy versus myocardial revascularization in chronic coronary syndrome and stable angina. Am J Med. 2011;124:681–688. [PubMed] [Google Scholar]

18. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 Guideline Update for the Management of Patients with Chronic Stable Angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol. 2003;41:159–168. [PubMed] [Google Scholar]

19. Thadani U. Current medical management of chronic stable angina. J Cardiovasc Pharmacol Ther. 2004;9(suppl 1):S11–S29. [PubMed] [Google Scholar]

20. Thadani U. Medical therapy of stable angina pectoris. Cardiol Clin. 1991;9:73–87. [PubMed] [Google Scholar]

21. Boden WE, O'Rourke RA, Teo KK, et al. Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial Veterans Affairs Cooperative Studies Program no. 424. Am Heart J. 2006;151: 1173–1179. [PubMed] [Google Scholar]

22. Fraker TD Jr, Fihn SD, Gibbons RJ, et al. 2007. Chronic Angina Focused Update of the ACC/AHA 2002 Guidelines for the Management of Patients with Chronic Stable Angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 Guidelines for the management of patients with chronic stable angina [published correction appears in Circulation. 2007;116:e558]. Circulation. 2007;116: 2762–2772. [PubMed] [Google Scholar]

23. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432–2446. [PubMed] [Google Scholar]

24. Terry T, Raravikar K, Chokrungvaranon N, et al. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT. Curr Cardiol Rep. 2012;14:79–88. [PubMed] [Google Scholar]

25. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559. [PMC free article] [PubMed] [Google Scholar]

26. Chamberlain DA, Fox KA, Henderson RA, et al; RITA‐2 trial participants. Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA‐2) trial. Lancet. 1997;350:461–468. [PubMed] [Google Scholar]

27. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta‐analysis. Circulation. 2005;111:2906–2912. [PubMed] [Google Scholar]

28. Caracciolo EA, Davis KB, Sopko G, et al. Comparison of surgical and medical group survival in patients with left main coronary artery disease: long‐term CASS experience. Circulation. 1995;91:2335–2344. [PubMed] [Google Scholar]

29. Peduzzi P, Kamina A, Detre K. Twenty‐two‐year follow‐up in the VA Cooperative Study of Coronary Artery Bypass Surgery for Stable Angina. Am J Cardiol. 1998;81:1393–1399. [PubMed] [Google Scholar]

30. Frye RL, August P, Brooks MM, et al; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503–2515. [PMC free article] [PubMed] [Google Scholar]

31. Kones R. Recent advances in the management of chronic stable angina II: anti‐ischemic therapy, options for refractory angina, risk factor reduction, and revascularization. Vasc Health Risk Manag. 2010;6:749–774. [PMC free article] [PubMed] [Google Scholar]

32. Graboys TB, Lown B. Cardiology patient page. Nitroglycerin: the “mini” wonder drug. Circulation. 2003;108:e78–e79. [PubMed] [Google Scholar]

33. Murell W. Nitroglycerin as a remedy for angina pectoris. Lancet. 1879;113:642–646. [Google Scholar]

34. Kimchi A, Lee G, Amsterdam E, et al. Increased exercise tolerance after nitroglycerin oral spray: a new and effective therapeutic modality in angina pectoris. Circulation. 1983;67:124–127. [PubMed] [Google Scholar]

35. Kolenda KD. Glycerol trinitrate and coronary heart disease: value of prophylactic administration within the scope of exercise therapy [article in German]. Fortschr Med. 1998;116:41–42. [PubMed] [Google Scholar]

36. Wittig T, Beuscher N. Increased physical performance following administration of glycerol trinitrate in spray form [article in German]. Fortschr Med. 1999;117:109–113. [Google Scholar]

37. Thadani U, Rodgers T. Side effects of using nitrates to treat angina. Expert Opin Drug Saf. 2006;5:667–674. [PubMed] [Google Scholar]

38. Thadani U, Opie L. Nitrates. In: Opie L, ed. Drugs for the Heart. 4th ed. Philadelphia: WB Saunders; 1995:36–37. [Google Scholar]

39. Zimrin D, Reichek N, Bogin KT, et al. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation. 1988;77:1376–1384. [PubMed] [Google Scholar]

40. Thadani U, Lipicky R. Short‐ and long‐acting nitrates for stable angina pectoris. In: Thadani U, Lipicky RJ, eds. Nitrates Updated: Current Use in Angina, Ischemia, Infarction, and Failure. Kluwer Academic Publications; (Springer; ); 1997:94–116. [Google Scholar]

41. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol. 1989;13:786–795. [PubMed] [Google Scholar]

42. Thadani U. Nitrate tolerance, rebound, and their clinical relevance in stable angina pectoris, unstable angina, and heart failure. Cardiovasc Drugs Ther. 1997;10:735–742. [PubMed] [Google Scholar]

43. Nitro‐Dur [prescribing information] . Summit, NJ: Key Pharmaceuticals, Inc.; 2006.

44. Nitrolingual Pumpspray [prescribing information]. Raleigh, NC: Arbor Pharmaceuticals, Inc.; 2011.. [Google Scholar]

45. Thadani U. Nitrate therapy and the development of tolerance. Arch Fam Med. 1993;2:880–885. [PubMed] [Google Scholar]

46. Thadani U, Whitsett T, Hamilton SF. Nitrate therapy for myocardial ischemic syndrome: current perspectives including tolerance. Curr Probl Cardiol. 1988;13:723–784. [PubMed] [Google Scholar]

47. Axelsson KL, Andersson RG. Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol. 1983;88:71–79. [PubMed] [Google Scholar]

48. Chen Z, Zhang J, Stamler JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002;99:8306–8311. [PMC free article] [PubMed] [Google Scholar]

49. Dakak N, Makhoul N, Flugelman MY, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1990;66:608–613. [PubMed] [Google Scholar]

50. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N‐acetylcysteine. J Am Coll Cardiol. 1990;16:923–931. [PubMed] [Google Scholar]

51. Fung H, Bauer JA. Mechanism of nitrate tolerance. In: Thadani U, Opie LH, eds. Nitrates Updated: Current Use in Angina, Ischemia, Infarction, and Failure. Kluwer Academic Publications; (Springer; ); 1997:57–79. [Google Scholar]

52. Gori T, Burstein JM, Ahmed S, et al. Folic acid prevents nitroglycerin‐induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study. Circulation. 2001;104:1119–1123. [PubMed] [Google Scholar]

53. Ignarro LJ, Lippton H, Edwards JC, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S‐nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981;218:739–749. [PubMed] [Google Scholar]

54. Katz RJ, Levy WS, Buff L, et al. Prevention of nitrate tolerance with angiotension‐converting enzyme inhibitors. Circulation. 1991;83:1271–1277. [PubMed] [Google Scholar]

55. Kobayashi A, Suzuki Y, Kamikawa T, et al. The effects of nitroglycerin on cyclic nucleotides in the coronary artery in vivo. Life Sci. 1980;27:1679–1685. [PubMed] [Google Scholar]

56. Kukovetz WR, Holzmann S. Mechanism of nitrate‐induced vasodilation and tolerance. Z Kardiol. 1983;72(suppl 3):14–19. [PubMed] [Google Scholar]

57. Münzel T, Holtz J, Mülsch A, et al. Nitrate tolerance in epicardial arteries or in the venous system is not reversed by N‐acetylcysteine in vivo, but tolerance‐independent interactions exist. Circulation. 1989;79:188–197. [PubMed] [Google Scholar]

58. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973;184:709–715. [PubMed] [Google Scholar]

59. Parker JO, Parker JD, Caldwell RW, et al. The effect of supplemental L‐arginine on tolerance development during continuous transdermal nitroglycerin therapy. J Am Coll Cardiol. 2002;39:1199–1203. [PubMed] [Google Scholar]

60. Sage PR, de la Lande IS, Stafford I, et al. Nitroglycerin tolerance in human vessels: evidence for impaired nitroglycerin bioconversion. Circulation. 2000;102:2810–2815. [PubMed] [Google Scholar]

61. Torresi J, Horowitz JD, Dusting GJ. Prevention and reversal of tolerance to nitroglycerine with N‐acetylcysteine. J Cardiovasc Pharmacol. 1985;7:777–783. [PubMed] [Google Scholar]

62. Watanabe H, Kakihana M, Ohtsuka S, et al. Randomized, double‐blind, placebo‐controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance. Circulation. 1997;96:2545–2550. [PubMed] [Google Scholar]

63. Watanabe H, Kakihana M, Ohtsuka S, et al. Randomized, double‐blind, placebo‐controlled study of carvedilol on the prevention of nitrate tolerance in patients with chronic heart failure. J Am Coll Cardiol. 1998;32:1194–1200. [PubMed] [Google Scholar]

64. Watanabe H, Kakihana M, Ohtsuka S, et al. Randomized, double‐blind, placebo‐controlled study of the preventive effect of supplemental oral vitamin C on attenuation of development of nitrate tolerance. J Am Coll Cardiol. 1998;31:1323–1329. [PubMed] [Google Scholar]

65. Watanabe H, Kakihana M, Ohtsuka S, et al. Preventive effects of carvedilol on nitrate tolerance—a randomized, double‐blind, placebo‐controlled comparative study between carvedilol and arotinolol. J Am Coll Cardiol. 1998;32:1201–1206. [PubMed] [Google Scholar]

66. Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799–804. [PubMed] [Google Scholar]

67. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association [published correction appears in J Am Coll Cardiol. 1999;34:1850]. J Am Coll Cardiol. 1999;33:273–282. [PubMed] [Google Scholar]

68. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000;36:25–31. [PubMed] [Google Scholar]

69. Kloner RA. Cardiovascular effects of the 3 phosphodiesterase‐5 inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004;110:3149–3155. [PubMed] [Google Scholar]

70. Muse (alprostadil) urethral suppository [package insert]. Somerset, NJ: Meda Pharmaceuticals; 2011.. [Google Scholar]

71. Bourke E, Sowes J. The autonomic nervous system and blook pressure regulation in the elderly. In: Kuchel GA, Hof PR, eds. Autonomic Nervous System in Old Age. Vol 33. Interdiscipl Top Gerontol. 2004:44–52. [Google Scholar]

72. Carasso S, Markiewicz W. Medical treatment of patients with stable angina pectoris referred for coronary angiography: failure of treatment or failure to treat. Clin Cardiol. 2002;25:436–441. [PMC free article] [PubMed] [Google Scholar]

73. Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association Scientific Statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation [published correction appears in Circulation. 2005;111:1717]. Circulation. 2005;111:369–376. [PubMed] [Google Scholar]

74. Taylor RS, Brown A, Ebrahim S, et al. Exercise‐based rehabilitation for patients with coronary heart disease: systematic review and meta‐analysis of randomized controlled trials. Am J Med. 2004;116:682–692. [PubMed] [Google Scholar]

75. Braverman DL. Cardiac rehabilitation: a contemporary review. Am J Phys Med Rehabil. 2011;90:599–611. [PubMed] [Google Scholar]

76. Thompson PD. Exercise prescription and proscription for patients with coronary artery disease. Circulation. 2005;112:2354–2363. [PubMed] [Google Scholar]

77. Hambrecht R, Walther C, Möbius‐Winkler S, et al. Percutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial. Circulation. 2004;109:1371–1378. [PubMed] [Google Scholar]

78. Berkman LF, Blumenthal J, Burg M, et al; Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) randomized trial. JAMA. 2003;289:3106–3116. [PubMed] [Google Scholar]

79. Parker JO, Vankoughnett KA, Farrell B. Nitroglycerin lingual spray: clinical efficacy and dose‐response relation. Am J Cardiol. 1986;57:1–5. [PubMed] [Google Scholar]

80. Beatty AL, Zhang MH, Ku IA, et al. Adiponectin is associated with increased mortality and heart failure in patients with stable ischemic heart disease: data from the Heart and Soul Study. Atherosclerosis. 2012;220:587–592. [PMC free article] [PubMed] [Google Scholar]

81. Maron DJ, Stone GW, Berman DS, et al. Is cardiac catheterization necessary before initial management of patients with stable ischemic heart disease? Results from a Web‐based survey of cardiologists. Am Heart J. 2011;162:1034.e13–1043.e13. [PubMed] [Google Scholar]

82. Kushner F. The New and Revised 2011. ACCF/AHA PCI and CABG Guidelines: A Revascularization Consensus Is at the Heart of the Matter. http://my.americanheart.org/professional/General/Revascularization‐Consensus‐is‐at‐the‐Heart‐of‐the‐Matter_UCM_433406_Article.jsp. Updated November 8, 2011. Accessed March 2, 2012.

83. Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 Guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation. 2003;107:149–158. [PubMed] [Google Scholar]

84. Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST‐EECP): effect of EECP on exercise‐induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999;33:1833–1840. [PubMed] [Google Scholar]

85. Barsness G, Feldman AM, Holmes DR Jr, et al. The International EECP Patient Registry (IEPR): design, methods, baseline characteristics, and acute results. Clin Cardiol. 2001;24:435–442. [PMC free article] [PubMed] [Google Scholar]

86. Lawson WE, Hui JC, Lang G. Treatment benefit in the enhanced external counterpulsation consortium. Cardiology. 2000;94:31–35. [PubMed] [Google Scholar]

87. Lopressor (metoprolol tartrate) tablets, USP [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.. [Google Scholar]

88. Nitrostat (nitroglycerin sublingual) tablets, USP [prescribing information]. New York, NY: Pfizer; 2011.. [Google Scholar]

89. Cardizem (diltiazem hydrochloride) extended release tablets [prescribing information]. Chicago, IL: Abbott Laboratories; 2010.. [Google Scholar]

90. Ranexa (ranolazine) extended‐release tablets [prescribing information]. Foster City, CA: Gilead Sciences, Inc.; 2011.. [Google Scholar]

Page 2

Side Effects, Precautions, and Contraindications of Antianginal Drugs19., 37., 87., 88., 89., 90.